Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974064 | 0.92 | MAPT (0.43) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1972719 | 0.91 | TRPM8 (0.41) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1974058 | 0.89 | ESR1 (0.40) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1976686 | 0.87 | SCN9A (0.42) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1976981 | 0.87 | TRPM8 (0.41) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1973531 | 0.85 | ESR1 (0.40) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1973428 | 0.83 | SMN1; SMN2 (0.41) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1974984 | 0.82 | ESR1 (0.46) | KDM4ENPC1RAB9ASMN1; SMN2ESR1 | |
| SCHEMBL1975336 | 0.81 | KDM4E (0.43) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1978256 | 0.81 | MAPT (0.48) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | MAPT 3256/4885KDM4E 679/4885NPC1 4098/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | MAPT 3256/4885KDM4E 679/4885NPC1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.